RE:RE:The CallBecause there was no news, other than ph3 being pushed back from Q1 to H1 2024. No definitive agreement news. No partnership news. Nothing. If Roche has any interest, and that is a big if, then they're laughing at Coffey's ineptitude at BD, and foreseeing the chance that the SP could go sub $2cad in 2024.